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Human T-lymphotropic virus type-1 (HTLV-1) can
cause the development of HTLV-1 associated myelopa-
thy/ tropical spastic paraparesis (HAM/TSP) and adult
T-cell leukemia (ATL). These nervous system inflamma-
tion and cancer occur only in a very small proportion of
infected individuals, indicating that several host and
viral factors might associate with the risk of HAM/TSP
or ATL.
The aim of this study is to identify a subset of pro-
teins which would be applicable as the therapeutic tar-
gets or biomarkers for HAM/TSP or ATL. For this
purpose, we employed comprehensive quantitative pro-
teomics technologies. Peripheral blood mononuclear
cells (PBMC) were collected from 6 uninfected volun-
teers, 4 asymptomatic carriers (AC), 10 HAM/TSP
patients, and 9 ATL patients, followed by the specific
selection of CD4+CD25+CCR4+ T cells, since this cell
population was known as the predominant viral reser-
voir. The sorted T cells from 29 individuals were lysed,
digested, and separately subjected to LC/MS/MS ana-
lyses. We integrated the 29 LC/MS/MS data into the
Expressionist proteome database server platform and
conducted label-free quantification analysis. The raw
mass spectrometric data sets were processed and quanti-
fied on the RefinerMS module and statistical analysis
was performed on the Analyst module. Eventually the
results of ANOVA and the leave-one-out cross valida-
tion test revealed that the 100 peptide-panel allowed the
clear classification of four pathological groups. In con-
clusion, our proteome profiling of CD4+CD25+CCR4+
T cells enabled us to identify the potential therapeutic
or biomarker targets for HAM/TSP and/or ATL, while
further validation studies with larger number of samples
should be necessary.
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